SCHEMBL10161183

SCHEMBL10161183

CCN1CCC(c2ccc(N3CCN(C(=O)OCc4ccccc4)CC3)cc2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 11/20 0.54
TMEM97 Q5BJF2 10/20 0.54
PDE4B Q07343 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
CHRM4 P08173 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
DRD1 P21728 1/20 0.49
HRH2 P25021 1/20 0.49
HTR1B P28222 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR1E P28566 1/20 0.49
SLC6A4 P31645 1/20 0.49
HRH1 P35367 1/20 0.49
HTR2B P41595 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31198857 0.82 GPR119 (0.57) SIGMAR1TMEM97PDE4BSMN1; SMN2NPC1
SCHEMBL10161329 0.80 CHRNA7 (0.60) SIGMAR1SMN1; SMN2DRD1KDM4EGAA
SCHEMBL9727540 0.79 NPSR1 (0.68) SIGMAR1TMEM97SMN1; SMN2NPC1RAB9A
SCHEMBL6132364 0.78 GAA (0.69) SIGMAR1TMEM97SMN1; SMN2NPC1RAB9A
SCHEMBL10243152 0.78 MEN1 (0.62) SIGMAR1TMEM97SMN1; SMN2NPC1RAB9A
SCHEMBL10162768 0.78 TDP1 (0.57) SMN1; SMN2MAPTCYP2C19MEN1KMT2A
SCHEMBL10130954 0.77 TMEM97 (0.51) SIGMAR1TMEM97SMN1; SMN2NPC1RAB9A
SCHEMBL3960449 0.77 SMN1; SMN2 (0.65) SIGMAR1TMEM97SMN1; SMN2NPC1RAB9A
SCHEMBL4035554 0.77 SMN1; SMN2 (0.72) PDE4BSMN1; SMN2NPC1RAB9ACHRM4
SCHEMBL10163586 0.77 MAPT (0.54) PDE4BHTR1ALMNAMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165320-A1 NOVEL AZABICYCLOHEXANES PANACEA BIOTEC LTD. (IN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165320-A1 NOVEL AZABICYCLOHEXANES CYP3A43, UGT1A1, CYP3A4 SIGMAR1 815/4885TMEM97 4343/4885PDE4B 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.